Abstract: A double-strand oligonucleotide including two complementary oligonucleotide sequences forming a hybrid, each including at one of their 3? or 5? ends, one to five unpaired nucleotides forming single-strand ends extending beyond the hybrid, one of the oligonucleotide sequences being substantially complementary to a target sequence belonging to a DNA or RNA molecule to be specifically repressed, the target sequence belonging to a DNA or RNA molecule of a gene coding an angiogenic factor.

Abstract: A double-strand oligonucleotide including two complementary oligonucleotide sequences forming a hybrid, each including at one of their 3? or 5? ends, one to five unpaired nucleotides forming single-strand ends extending beyond the hybrid, one of the oligonucleotide sequences being substantially complementary to a target sequence belonging to a DNA or RNA molecule to be specifically repressed, the target sequence belonging to a DNA or RNA molecule of a gene coding an angiogenic factor.

Abstract: A method of treating a disease resulting from the expression of a harmful gene is described. The method includes the step of administering a therapeutically effective amount of a pharmaceutical composition having at least one double stranded oligonucleotide including two complementary oligonucleotide sequences forming a hybrid. Each oligonucleotide sequence comprises at one of their 3? or 5? ends one to five unpaired nucleotides forming single-strand ends extending beyond the hybrid. One of the oligonucleotide sequences is substantially complementary to a target sequence belonging to a DNA or messenger RNA molecule of a gene coding a mutated or nonmutated androgen receptor.

Abstract: A method for inducing activity of a specific RNAi into eukaryote cells in which the TAT protein and a nucleic acid coding for a nucleotide sequence comprising the sense and antisense sequences of an RNAi of interest are introduced, which sense and antisense sequences are separated by a separating nucleotide sequence coding for a sequence comprising at least the minimal TAR sequence recognized by the TAT protein, which transcribed separating sequence and the TAT protein form a complex that inhibits the activity of the RNAi of interest, and the activity of the RNAi is induced by withdrawing the TAT protein.

Abstract: The invention concerns a double-stranded oligonucleotide characterized in that it consists of two complementary oligonucleotide sequences forming a hybrid comprising each at one of their 3? or 5? ends one to five non-matched nucleotides forming single-stranded ends overlapping from the hybrid, one of said oligonucleotide sequences being substantially complementary of a target sequence belonging to a DNA or RNA molecule to be specifically repressed. The invention also concerns the use of said oligonucleotides in pharmaceutical compositions for treating cancers.